Your browser doesn't support javascript.
loading
JME-001 phase II trial of first-line combination chemotherapy with cisplatin, pemetrexed, and nivolumab for unresectable malignant pleural mesothelioma.
Miyamoto, Yosuke; Kozuki, Toshiyuki; Aoe, Keisuke; Wada, Sae; Harada, Daijiro; Yoshida, Michihiro; Sakurai, Jun; Hotta, Katsuyuki; Fujimoto, Nobukazu.
Afiliação
  • Miyamoto Y; Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan.
  • Kozuki T; Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
  • Aoe K; Department of Medical Oncology, National Hospital Organization Yamaguchi-Ube Medical Center, Ube, Japan.
  • Wada S; Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan.
  • Harada D; Department of Thoracic Oncology and Medicine, National Hospital Organization Shikoku Cancer Center, Matsuyama, Japan.
  • Yoshida M; Center of Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
  • Sakurai J; Center of Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
  • Hotta K; Center of Innovative Clinical Medicine, Okayama University Hospital, Okayama, Japan.
  • Fujimoto N; Department of Medical Oncology, Okayama Rosai Hospital, Okayama, Japan nobufujimot@gmail.com.
J Immunother Cancer ; 9(10)2021 10.
Article em En | MEDLINE | ID: mdl-34711664

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pleurais / Protocolos de Quimioterapia Combinada Antineoplásica / Cisplatino / Pemetrexede / Nivolumabe / Mesotelioma Maligno Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias Pleurais / Protocolos de Quimioterapia Combinada Antineoplásica / Cisplatino / Pemetrexede / Nivolumabe / Mesotelioma Maligno Idioma: En Ano de publicação: 2021 Tipo de documento: Article